Dear all,   Compliments of the season! Here is the first update of 2023. Reminder: If you would like to advertise the work of your NITAG through these monthly update, you can contact me with your recommendation.If your NITAG would like to become a GNN member, please send me an email with the contact details of the chair and the secretariat.If ...

Dear all,   This is the last update of 2022!   COVID-19: Booster dose: French NITAG has preferentially recommended bivalent vaccines suitable for Omicron, regardless of the vaccine(s) previously administered. The full recommendation on booster vaccine strategy is available here. The French NITAG recommends integrating the Nuvaxovid vaccin...

Dear all,   The end of this year is fast approaching and the monthly updates 22’ will also pause during the December break. In November, our article based on the survey conducted through the GNN on COVID-19 vaccine policy development was finally published and is accessible in open access here: https://www.sciencedirect.com/science/article/pii/...

Dear all,   Here is the October update and this month is ending with the GNN webinar. We discussed the recent SAGE recommendations on monkeypox and COVID-19 variant-containing vaccines as well as the access and programmatic implications for future COVID-19 vaccination. The meeting presentations will be circulated separately but the recording i...

Dear all,   Here comes the end of September, the fall season and the second ordinary SAGE meeting! NITAGs are getting back to other topics than COVID-19 vaccines and COVID-19 working groups are meeting less often - this will hopefully allow NITAG members to tackle the decrease in childhood immunization coverage and the ambitious IA2030 objecti...

Dear all,   I hope everyone enjoyed a break over the summer/winter depending on where you are in the world.   COVID-19 vaccines Novavax: On July 19, 2022, the ACIP made an interim recommendation for use of the Novavax vaccine in persons aged ≥18 years as a primary 2-dose series vaccination for the prevention of COVID-19, available here al...

Subject: GNN monthly update July' 22   Dear all,   This month ends with two great meetings where some of you were able to meet face-to-face and it is always a pleasure to see the NITAG community so vibrant. 3 main points from this monthly update: a SAGE extraordinary meeting is being held on August 11th to discuss Valneva vaccine, second ...

Dear all,   Here comes the June update focusing mostly on COVID-19 vaccines and Monkeypox outbreak response.   NITAG publications and updates:   COVID-19 additional Booster doses: ATAGI (Australia) recommends a first booster dose for adolescents (12-15 years old) who are severely immunocompromised, who have a disability with signific...

NITAG publications and updates:   COVID-19 additional Booster doses: CDC provided clinical considerations for a Second COVID-19 Vaccine Booster Dose, summarized in a one pager here.NACI released initial guidance on a second booster dose of COVID-19 vaccines in Canada, urging jurisdictions to prepare for the rapid deployment...

Dear all,   Please find attached the agenda for the GNN webinar of May 2nd at 2pm. We hope to see you there.   NACI would also like to share with the NITAG community the following information that may be of interest to you:   We are from the Public Health Agency of Canada (PHAC) writing to you about our recent public consultation on ...

NITAG publications and updates:   COVID-19 Booster vaccination: NACI updated its guidance on a first booster dose of COVID-19 vaccines in Canada. In particular: NACI has strengthened the following recommendations from ‘may’ to ‘should,’ so that now all adults 18 years of age and over are strongly recommended to receive a booster dose: A first ...

NITAG publications and updates:   COVIFENZ: NACI recommends the Medicago Covifenz COVID-19 vaccine for use as a primary series in people 18 to 64 years of age. This is the first plantbased virus-like particle (VLP) vaccine authorized for use in Canada. Clinical trials show the Medicago Covifenz COVID-19 vaccine has a good safety profile and is...

Dear all, Please find below the GNN monthly update for February’ 22:   NITAG publications and updates:   COVID-19 booster Doses: ATAGI (Australia) recommends the use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years. The statement is available here. Of note, Pfizer vaccine is the only brand currently registered ...

Dear all, Best wishes to all of you for this new year! The year started with a first extraordinary SAGE meeting on January 19th which focused on major revision to the WHO SAGE Roadmap for Prioritizing Use of COVID-19 Vaccines. While the previous version of the Roadmap was developed in the context of  vaccine supply constraints, this updated ve...

Please find below the GNN monthly update for December’ 21:   NITAG publications and updates:   COVID-19 additional and booster Doses: NACI (Canada) has updated its booster recommendations.NACI strongly recommends a booster dose of an authorized mRNA COVID-19 vaccine should be offered at least 6 months after completion of a primary COVID19...

Dear all, Thank you all who could participate in the GNN webinar yesterday. It has been very fruitful to hear current situations on booster vaccination and timing for the booster dose as well as challenges on product specific vaccines. We also hope that you will make the most of the Sysvac registry. All the presentations are available here. The rec...

Please find below the GNN monthly update for November 21: NITAG publications and updates:   COVID-19 additional and booster Doses: NACI (Canada) strongly recommends that populations at highest risk of waning protection following their primary series and at highest risk of severe COVID-19 illness should be offered a booster dose of an mRNA COVI...

Please find below the GNN monthly update for September’ 21:   NITAG publications and updates:   COVID-19 booster Dose: JCVI (UK) has issued updated advice on COVID-19 booster vaccination.The Belgian NITAG recommends an additional dose of mRNA COVID-19 vaccine for older adults (age cut-off: 65 years). The advice is available in French here...